We have developed a novel, rapid microassay for dichloroacetate in the serum. The serum sample is directly injected into a gel-permeation high-performance liquid chromatography apparatus. The peak of dichloroacetate appears after a giant protein peak. The method requires a very small amount of serum (10 ), and the analysis time is short (20 min). Using this micro method, we measured the serum concentrations of dichloroacetate in healthy adult volunteers and paediatric patients with congenital lactic acidosis. Although the effect of dichloroacetate on the neurological manifestations of congenital lactic acidosis has not been proved to be beneficial, the potential usefulness of dichloroacetate in refractory lactic acidosis in cardiac and respiratory failure has been recognized, and human äs well äs animal studies have been undertaken in many laboratories. To prevent possible side effects of dichloroacetate, it has been recommended that the minimal effective dose be used. Our microassay method is useful for both human and animal experiments, even after administration of minimal doses.
Introduction
Dichloroacetate äs the sodium salt has been used for the treatment of hyperglycaemia, lactic acidosis, and hypercholesterolaemia (1) (2) (3) (4) (5) (6) (7) . Although dichloroacetate has many metabolic effects on glucose, lipid and amino acid metabolism, its main pharmacologic effect has been shown to be the activation of the pyruvate dehydrogenase 1 ) complex by inhibiting pyruvate dehydrogenase ki-
The clinical usefulness of dichloroacetate has been hampered by its possible toxic and mutagenic effects (7) . Peripheral neuropathy and testieular atrophy have been reported in humans äs well äs animals after chronic administration of dichloroacetate (12) . Recently, however, dichloroacetate has been reevaluated in response to the many reports on its efficacy in the refractory acidosis encountered in emergency medicine, such äs cardiac arrest and septic shock (13 -15) .
Although there have been few reports on the acute toxicity of dichloroacetate, it has been recommended that the minimal effective dose be used in order to prevent possible adverse effects (7) . Dichloroacetate has been measured by gas-chromatography (11) , but the measurement is time-consuming and requires 2 ml of blood. Because of these technical difficulties, blood concentrations of dichloroacetate have not been routinely measured.
In the present study, we have developed a rapid micromethod for dichloroacetate measurement using gel permeation chromatography. With this micromethod, we have investigated the pharmacokinetics of dichloroacetate by measuring its level in serum in various patients with lactic acidosis, äs well äs in healthy adult volunteers. Since the new method requires a very small amount of serum (10 ) , and needs no extraction procedure for sample preparation, it is suitable for measuring serum concentrations of dichloroacetate in human äs well äs animal experiments. 
Materials and Methods
Dichloroacetate (sodium salt) was purchased from Tokyo Kasei (Tokyo). The other cheraicals were of the highest quality available and obtained frorn Standard sources.
Blood samplcs were drawn from patients with lactic acidosis of various actiologies and from normal adult volunteers. The basic disorders of thc patients and doses of dichloroacetate are summarized in table 1. Informed consent was obtained from the parents of thc patients betöre dichloroacetate administration. The volunteers werc given 35 mg/kg of dichloroacetate orally. Blood samples were drawrfbeforc and after oral dichloroacetate loading at 30 minutes intervals. Serum was separated immediately and kept frozen at -20 °C until analysis.
A small amount (15 to 25 ) of serum was directly injected into a high-performance liquid chromatography (HPLC) apparatus. A gel-permeation HPLC column (Asahipak GS-320, Asahi Kasei, Tokyo) was equipped with a pump (Waters, Model 6000A) and UV spectrophotometer (Soma UV detector, Soma Kogaku, Tokyo). The column was eluted with 0.01 mol/1 ammonium acetate (pH 4.0)/ acetonitrile (9+1, by vol.) at a flow rate of 2.0 ml/min, and the eluate was monitored at 220 nm. The quantitation of dichloroacetate was carried out by comparing the peak height of dichloroacetate with the calibration curve constructed by plotting the peak heights of various known amounts of dichloroacetate.
Dichloroacetate was also measured by gas-chromatography according to the method of Wells et al. (11) with trichloroacetic acid äs the internal Standard.
Results

The new Chromatographie method of dichloroacetate measurement
The chromatogram of normal serum is shown in figure l a. In the gel-permeation column, molecules whose sizes are greater than M r 40 000 are excluded from the column bed, and the smaller molecules are retained in the column for various times according to the interaction between the molecules and the packing material. Thus the chromatogram of normal serum consists of a giant peak which represents the serum components with molecular mass greater than 40000 (mostly proteins) and several unknown peaks following it. The chromatogram of the serum from a volunteer after dichloroacetate intake is shown in figure Ic. As shown in the figures, a distinct peak appeared at 12.2 min. A peak with exactly the same retention time was observed when serum pre- figure 2 . The minimal ineasurable concentration was 5 mg/1 when 25 of serum was injected, but a much lower coricenträtion was measurable by increasing the amount injected, orby increasing the sensitivity of the UV detector. To assess the reproducibility of the method, we injected replicate aliquots of the sample. The coefficient of Variation (CV) was found to be very small (CV = 2.4%, n = 8).
We measured the levels of dichloroacetate in 9 serum samples by conventional gas chromatography concomi- Finally, the specificity of the method was ascertained by injecting the sera from 10 patients who were taking different drugs (antiepileptic drugs, antibiotics) into the HPLC. No peaks were observed around the retention time of the dichloroacetate peak (data not shown).
Pharmacokinetics of dichloroacetate in healthy adult volunteers
Using the micromethod, we investigated the pharmacokinetics of dichloroacetate in healthy adults. The time course of the levels of dichloroacetate in two volunteers is shown in figure 4 . The dichloroacetate was absorbed quickly and reached a peak concentration within 30-60 minutes. The level then dropped rapidly, and by 5 hours dichloroacetate had disappared from the serum. 
Measurement of serum dichloroacetate levels in patients
The typical time course of serum dichloroacetate concentrations is shown in figures 5a and 5b. In patients l, 2 and 3, dichloroacetate had been orally administrated for various periods previously. In Patients 2, 3 and 4, the attained peak levels of dichloroacetate were different, although the doses of dichloroacetate per body weight were similar. It was also shown that the ratio of dose to blood level was not linear, äs indicated by the very high levels of dichloroacetate in Patient 1. The very prolonged half-life of dichloroacetate in Patient l suggests an impaired elimination of dichloroacetate from the circulation in this case.
Discussion
We demonstrated that the micromethod for dichloroacetate measurement is useful for monitoring serum dichloroacetate. Once the HPLC apparatus was set up, it usually took only 20 minutes to obtain the results. In the conventional gas-chromatographic method, it would take at least several hours, since deproteinization and derivatization of dichloroacetate must be performed before the Chromatographie measurement (11) . Addition of internal Standard is also required in the gas^chromato-graphic method. Furthermore, the new method requires much less sample: the gas-chromatographic method requires l ml of serum, whereas äs little äs 10 is enough for the micro method. The serum contained in a glass capillary is sufficient for the measurement of dichloroacetate by the new method. We are therefore able to monitor dichloroacetate concentrations even in small animals.
The pharmacokinetics of dichloroacetate determined by the micro method are comparable with the previously reported values obtained with a single intravenous injection (5, 11, 17, 18) . Although the accurate calculation of the half-life was difficult when the drug was administrated orally, we estimated the approximate half life of dichloroacetate by a modified calculation method of Wagner & Nelson (16) . In healthy adults, the half-life was approximately 30 minutes, although the calculated half-life of dichloroacetate was much longer than this in Patient 1. It has been reported that the elimination of dichloroacetate from the circulation follows Saturation kinetics (11) , and tissue accumulation of dichloroacetate occurs when dichloroacetate is administered for a long time. Adverse effects such äs polyneuropathy and testicular atrophy have been reported after chronic dichloroacetate treatment in human and animal studies (7, 12) . Cönsidering the unpredictability of exact blood levels of diehloroacetate, it is pertinent to measure them in pätients treated with dichloroacetate. The fact that dichloroacetate therapy has not yet been accepted äs a Standard therapy for lactic acidosis is mainly due to its possible toxic side-effects. It is important to maintain the reported minimum therapeutic level (130 mg/1) of dichloroacetate (11) . Although it is undoubtedly effective in lowering blood lactate and pyruvate in pätients with congenital lactic acidosis, it has been reported to show little effect in improving existing neurologic Symptoms (7) . Recently, however, its potential clinical usefulness has been reappraised, especially in critical care medicine (13 -15) . It has been demonstrated that dichloroacetate is effective in correcting severe acidosis refractoiy to the conventional sodium bicarbonate administration. It has also been shown that it has a protective effect against myocardial ischaemic damage. To confirm its potential clinical usefulness, many laboratories have been eonducting animal experiments to determine its efficacy and safety. Our micromethod is suitable for monitoring blood dichloroacetate concentrations in animal experiments äs well äs in clinical trials.
